Core Insights - Baijin Life Sciences (01466.HK) has signed a strategic cooperation framework agreement with Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. to invest in Youhuan through equity subscription, aiming to establish a leading global circRNA technology research platform and enhance innovation in cell therapy [1][2] Group 1: Company Overview - Youhuan is a dual-driven biopharmaceutical company focusing on circRNA technology platform research and innovative drug development, while also providing CRO services [2] - The company has successfully obtained U.S. patent authorization for its proprietary "Circular RNAs and Preparation Methods" and a Chinese invention patent for a method based on ribozyme self-splicing [2] Group 2: Collaboration Focus - The initial collaboration will prioritize exploring long-acting, stable expression of cytokines and enzymes for treating liver metabolic diseases [3] - Development of circRNA delivery systems using exosome and cell delivery technologies, leveraging Youhuan's platforms [3] - Engineering enhanced exosome and cell drugs for cardiovascular and tissue repair applications, targeting conditions such as myocardial infarction, stroke, and neurodegenerative diseases like Alzheimer's and Parkinson's [3] - Development of precise, efficient, and safe cell reprogramming and differentiation technologies for genetic disease treatment [3]
佰金生命科学(01466.HK)附属北京佰金将透过认购优环生物股权的方式对优环生物进行投资